Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04482491
Other study ID # Endoscopic Characterization
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2019
Est. completion date January 1, 2020

Study information

Verified date July 2020
Source Hôpital Edouard Herriot
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Colorectal cancer has become a public health priority considering its increased prevalence and high mortality rate when diagnosed late. As a consequence, many countries have promoted and uptaken of colorectal cancer screening programs leading to an increasing detection of advanced but also superficial lesions ESGE (European Society of Gastrointestinal Endoscopy) guidelines states that the majority of those colonic and rectal superficial lesions can be removed in a curative way by standard polypectomy and/or by EMR (Endoscopic Mucosal Resection) and that ESD (Endoscopic Submucosal Dissection) can be considered for removal of colonic and rectal lesions with high suspicion of limited submucosal invasion. Histologically, a resection is curative for the patient when the adenocarcinoma is well-differentiated (G1/G2), with a depth of invasion ≤ sm1 (≤ 1 mm submucosal invasion), with no lymphovascular invasion nor budding and with lateral and deep margins free of cancer


Recruitment information / eligibility

Status Completed
Enrollment 90
Est. completion date January 1, 2020
Est. primary completion date January 1, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria:

Patients with colorectal lesions> 2 cm because any gastroenterologist must be able to resect 2 cm polyps on their own and therefore should never need to take biopsies to clarify the histology before resection.

Patient consenting after information If the lesion is defined by an endoscopist as CONECCT IIA, simple adenoma, the lesion will be resected by en bloc mucosectomy or piece meal depending on its size (after a biopsy, secondary objective).

If the lesion is defined by an endoscopist as CONECCT IIC, adenoma at risk or superficial cancer (<1000µm depth), the lesion will be resected by R0 en bloc by mucosectomy or dissection if the lesion is greater than 20mm (after a biopsy, secondary objective).

If the lesion is defined by an endoscopist as CONECCT III, deep adenocarcinoma (=1000µm depth), it will be sampled from the most severe part by biopsy forceps and the patient will be referred to oncology or surgery according to the extension assessment .

Pathology available of endoscopic or surgical resection piece Follow-up at 6 months after treatment for CONECCT IS, IIA, IIC lesions by endoscopic control and III by clinical or imaging control.

.

-

Exclusion Criteria:

Metastatic lesion immediately before colonoscopy Patients under guardianship Age <18 Pregnant woman Contraindication to colonoscopy.

-

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Endoscopic Submucosal Dissection
Endoscopic Submucosal Dissection

Locations

Country Name City State
France Edouard Herriot Hospital Lyon Rhône Alpes

Sponsors (1)

Lead Sponsor Collaborator
Hôpital Edouard Herriot

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary correlation between the histological prediction according to the CONECCT classification, the directed biopsy, the non-directed biopsy and the final histology of the completely resected part (R0). 1 Year
See also
  Status Clinical Trial Phase
Recruiting NCT01132469 - Efficacy and Safety Study of Endoscopic Submucosal Dissection for Early Gastric Cancer N/A
Not yet recruiting NCT05736705 - Monopolar and Bipolar in Esophageal ESD N/A
Recruiting NCT02989818 - Multi-center Evaluation of the Clinical Utility of ESD in the Western Population
Recruiting NCT04780256 - Endoscopic Resection of Gastrointestinal Neoplasms
Completed NCT05265221 - Learning Curve for Gastric Endoscopic Submucosal Dissection
Recruiting NCT05407870 - Efficacy and Safety of Etomidate Sedation in Gastric Endoscopic Submucosal Dissection N/A
Completed NCT01394861 - Endoscopic Submucosal Dissection (ESD)- Master Slave Robotic System - Human Study Phase 0
Completed NCT03220334 - Healing Effects of Autologous Platelet Rich Plasma on Gastric Ulcer Caused by Endoscopic Submucosal Dissection Phase 3
Recruiting NCT05323929 - The Relationship Between Scar Formation and ESD Depth in Therapy for Gastric Carcinoma N/A
Completed NCT01879904 - Evaluation of Endoscopic Submucosal Dissection (ESD) Efficacy N/A
Recruiting NCT03039309 - Endoscopic Submucosal Dissection for Early GI Neoplasia in the United Kingdom
Completed NCT02931149 - Evaluation of the Efficacy of Platelet-rich Plasma (PRP) on Advanced Endoscopic Resection Techniques Phase 3